Phio Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 results were largely in-line with consensus on EPS while showing better-than-expected loss management. Revenue remained at zero, consistent with its clinical-stage status, while GAAP Net Loss of $4.14M beat the $4.27M consensus loss estimate. A significant R&D ramp-up (up 187% YoY) was offset by disciplined G&A, and the cash runway into H2 2027 provides a stable foundation for the upcoming PH-762 FDA meeting in Q3 2026.